» Articles » PMID: 29356624

From Genomics to Omics Landscapes of Parkinson's Disease: Revealing the Molecular Mechanisms

Overview
Journal OMICS
Date 2018 Jan 23
PMID 29356624
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Molecular mechanisms of Parkinson's disease (PD) have already been investigated in various different omics landscapes. We reviewed the literature about different omics approaches between November 2005 and November 2017 to depict the main pathological pathways for PD development. In total, 107 articles exploring different layers of omics data associated with PD were retrieved. The studies were grouped into 13 omics layers: genomics-DNA level, transcriptomics, epigenomics, proteomics, ncRNomics, interactomics, metabolomics, glycomics, lipidomics, phenomics, environmental omics, pharmacogenomics, and integromics. We discussed characteristics of studies from different landscapes, such as main findings, number of participants, sample type, methodology, and outcome. We also performed curation and preliminary synthesis of multiple omics data, and identified overlapping results, which could lead toward selection of biomarkers for further validation of PD risk loci. Biomarkers could support the development of targeted prognostic/diagnostic panels as a tool for early diagnosis and prediction of progression rate and prognosis. This review presents an example of a comprehensive approach to revealing the underlying processes and risk factors of a complex disease. It urges scientists to structure the already known data and integrate it into a meaningful context.

Citing Articles

Evaluation of Salivary Diagnostics: Applications, Benefits, Challenges, and Future Prospects in Dental and Systemic Disease Detection.

AlBagieh H, Alshehri A, Alduraywishi A, Aldaws A, AlBalawi S, Abu Shaqqaf H Cureus. 2025; 17(1):e77520.

PMID: 39958008 PMC: 11830415. DOI: 10.7759/cureus.77520.


Cross-disease transcriptomic analysis reveals DOK3 and PAPOLA as therapeutic targets for neuroinflammatory and tumorigenic processes.

Wang X, Bian Y, Chen W Front Immunol. 2024; 15:1504629.

PMID: 39726593 PMC: 11669587. DOI: 10.3389/fimmu.2024.1504629.


The role of inflammation in neurological disorders: a brief overview of multiple sclerosis, Alzheimer's, and Parkinson's disease'.

Cantero-Fortiz Y, Boada M Front Neurol. 2024; 15:1439125.

PMID: 39539666 PMC: 11558529. DOI: 10.3389/fneur.2024.1439125.


Integrative approach of omics and imaging data to discover new insights for understanding brain diseases.

Yoon J, Lee H, Kwon D, Lee D, Lee S, Cho E Brain Commun. 2024; 6(4):fcae265.

PMID: 39165479 PMC: 11334939. DOI: 10.1093/braincomms/fcae265.


Refining the clinical diagnosis of Parkinson's disease.

Mulroy E, Erro R, Bhatia K, Hallett M Parkinsonism Relat Disord. 2024; 122:106041.

PMID: 38360507 PMC: 11069446. DOI: 10.1016/j.parkreldis.2024.106041.


References
1.
Lee J, Lee E, Park S, Lim J, Kim H, Kim J . Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson's disease. Mov Disord. 2009; 24(12):1803-10. DOI: 10.1002/mds.22678. View

2.
Kori M, Aydin B, Unal S, Arga K, Kazan D . Metabolic Biomarkers and Neurodegeneration: A Pathway Enrichment Analysis of Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis. OMICS. 2016; 20(11):645-661. DOI: 10.1089/omi.2016.0106. View

3.
Halbgebauer S, Ockl P, Wirth K, Steinacker P, Otto M . Protein biomarkers in Parkinson's disease: Focus on cerebrospinal fluid markers and synaptic proteins. Mov Disord. 2016; 31(6):848-60. DOI: 10.1002/mds.26635. View

4.
Lubomski M, Rushworth R, Tisch S . Hospitalisation and comorbidities in Parkinson's disease: a large Australian retrospective study. J Neurol Neurosurg Psychiatry. 2014; 86(3):324-30. DOI: 10.1136/jnnp-2014-307822. View

5.
Maver A, Peterlin B . Positional integratomic approach in identification of genomic candidate regions for Parkinson's disease. Bioinformatics. 2011; 27(14):1971-8. DOI: 10.1093/bioinformatics/btr313. View